News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,805 Results
Type
Article (8021)
Company Profile (140)
Press Release (476547)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166770)
Career Advice (306)
Deals (25740)
Drug Delivery (7)
Drug Development (52879)
Employer Resources (14)
FDA (9761)
Job Trends (8578)
News (238247)
Policy (17930)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (486)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33155)
ALS (105)
Alzheimer's disease (976)
Antibody-drug conjugate (ADC) (264)
Approvals (10378)
Artificial intelligence (321)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6958)
BIO (36)
Biologics (2)
BIOSECURE Act (1)
Biosimilars (109)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (29)
Breast cancer (510)
Cancer (3653)
Cardiovascular disease (218)
Career advice (246)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (479)
Cervical cancer (34)
Clinical research (47877)
Collaboration (1245)
Commercialization (3)
Compensation (1470)
Complete response letters (34)
COVID-19 (754)
CRISPR (64)
C-suite (751)
Cystic fibrosis (85)
Data (5663)
Denatured (4)
Depression (102)
Dermatology (62)
Diabetes (345)
Diagnostics (4186)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (155)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (164)
Earnings (73716)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87623)
Executive appointments (701)
FDA (12399)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (920)
Gene editing (126)
Generative AI (9)
Gene therapy (319)
GLP-1 (290)
Government (942)
Grass and pollen (2)
Guidances (281)
Healthcare (9318)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (157)
Infectious disease (942)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (255)
Interviews (41)
IPO (12387)
IRA (2)
Job creations (1968)
Job search strategy (236)
JPM (1)
Kidney cancer (16)
Labor market (1)
Layoffs (59)
Legal (5195)
Licensing (8)
Liver cancer (44)
Longevity (17)
Lung cancer (509)
Lymphoma (251)
Machine learning (27)
Management (3)
Manufacturing (534)
Marketing (8)
MASH (118)
Medical device (8658)
Medtech (8803)
Mergers & acquisitions (14384)
Metabolic disorders (710)
mRNA (55)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (39)
Neuroscience (1826)
NextGen: Class of 2026 (3150)
Non-profit (841)
Now hiring (1)
Obesity (225)
Opinion (10)
Ovarian cancer (159)
Pain (172)
Pancreatic cancer (197)
Parkinson's disease (201)
Partnered (12)
Patents (476)
Patient recruitment (509)
Peanut (31)
People (41241)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15471)
Phase 2 (21382)
Phase 3 (14400)
Pipeline (7344)
Policy (18)
Postmarket research (1570)
Preclinical (6540)
Press Release (34)
Prostate cancer (190)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (575)
Real estate (3019)
Recruiting (6)
Regulatory (14831)
Reports (21)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (100)
Series A (156)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2019)
Stomach cancer (3)
Supply chain (50)
Vaccines (323)
Venture capital (17)
Weight loss (73)
Women's health (79)
Date
Today (46)
Last 7 days (213)
Last 30 days (1581)
Last 365 days (19042)
2026 (12344)
2025 (19252)
2024 (22986)
2023 (26538)
2022 (34587)
2021 (37178)
2020 (33468)
2019 (23256)
2018 (17493)
2017 (18766)
2016 (17917)
2015 (24268)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (305)
Arkansas (11)
Asia (17896)
Australia (2098)
California (11990)
Canada (3148)
China (525)
Colorado (485)
Connecticut (409)
Delaware (208)
Europe (24628)
Florida (1789)
Georgia (380)
Hawaii (3)
Idaho (46)
Illinois (700)
India (51)
Indiana (314)
Iowa (15)
Japan (403)
Kansas (101)
Kentucky (30)
Louisiana (27)
Maine (26)
Maryland (1202)
Massachusetts (7863)
Michigan (308)
Minnesota (560)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (116)
New Hampshire (60)
New Jersey (2621)
New Mexico (12)
New York (2822)
North Carolina (1280)
North Dakota (4)
Northern California (6003)
Ohio (278)
Oklahoma (14)
Oregon (16)
Pennsylvania (2253)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4984)
Tennessee (120)
Texas (1942)
United States (38904)
Utah (360)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (929)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
484,805 Results for "genedit inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BreezeBio (Formerly GenEdit) Announces Series B Financing to Advance Internal Pipeline of Precision Genetic Medicines
February 25, 2026
·
4 min read
Business
GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease
GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy® platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, a member of the Roche Group.
January 23, 2024
·
2 min read
Press Releases
GenEdit Appoints Dr. J. Rodrigo Mora as Chief Scientific Officer to Expand Its NanoGalaxy® Genetic Medicine Platform into Immunology
November 13, 2024
·
3 min read
Biotech Bay
GenEdit Announces Series A Financing and Provides Research Update at TIDES 2021
GenEdit, Inc today announced that it has closed a $26 million Series A financing.
September 23, 2021
·
3 min read
Biotech Bay
GenEdit Uncloaks to Solve Gene Editing “Delivery Problem”
Kunwoo Lee has uncloaked his solution to the gene-editing “delivery problem” with $26 million in Series A funds for his company, GenEdit.
September 23, 2021
·
3 min read
·
Kate Goodwin
Business
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
Sarepta and GenEdit will work together to identify development candidates for further testing.
February 1, 2022
·
7 min read
Business
GenEdit Expands Leadership Team to Advance Targeted Genetic Medicines into Clinical Trials
GenEdit, Inc., a biotechnology company with a mission to develop curative therapies through targeted in vivo delivery of genetic medicines, announced that it has added two accomplished industry executives to its leadership team.
September 22, 2021
·
3 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Business
Sarepta and GenEdit Expand Partnership to Transcend Gene Therapy Challenges
Together, these two companies are combining their strengths to find treatment options for rare neuromuscular diseases.
February 1, 2022
·
2 min read
·
Hannah Chudleigh
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
1 of 48,481
Next
